Baylor Genetics Featured in Human Mutation Journal for Their Research on The Expanding Clinical Phenotype of Germline ABL1-Associated Congenital Heart Defects and Skeletal Malformations Syndrome

The expanding clinical phenotype of germline ABL1-associated congenital heart defects and skeletal malformations syndrome

Chun‐An Chen, Emeline Crutcher, Harinder Gill, Tanya N. Nelson, Laurie A. Robak, Marjolijn C. J. Jongmans, Rolph Pfundt, Chitra Prasad, Roberta A. Berard, Madeleine Fannemel, Eirik Frengen, Doriana Misceo, Keri Ramsey, Yaping Yang, Christian P. Schaaf, Xia Wang

Published: July 9, 2020

Abstract

Congenital heart defects and skeletal malformations syndrome (CHDSKM) is a rare autosomal dominant disorder characterized by congenital heart disease, skeletal abnormalities, and failure to thrive. CHDSKM is caused by germline mutations in ABL1. To date, three variants have been in association with CHDSKM. In this study, we describe three de novo missense variants, c.407C>T (p.Thr136Met), c.746C>T (p.Pro249Leu), and c.1573G>A (p.Val525Met), and one recurrent variant, c.1066G>A (p.Ala356Thr), in six patients, thereby expanding the phenotypic spectrum of CHDSKM to include hearing impairment, lipodystrophy-like features, renal hypoplasia, and distinct ocular abnormalities. Functional investigation of the three novel variants showed an increased ABL1 kinase activity. The cardiac findings in additional patients with p.Ala356Thr contribute to the accumulating evidence that patients carrying either one of the recurrent variants, p.Tyr245Cys and p.Ala356Thr, have a high incidence of cardiac abnormalities. The phenotypic expansion has implications for the clinical diagnosis of CHDSKM in patients with germline ABL1 variants.

Human Mutation (2020) 

Click here to read the article. 

For more information on the products and/or services mentioned…

Previous Post
Genetics in Medicine Features Baylor Genetics for Study on Autosomal Recessive Genetic Diseases
Next Post
Baylor Genetics Featured in ScienceDirect for Research on Untargeted Metabolomics